Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Alison Lawton
AddedMar 31, 2024
UpdatedMay 31, 2026
Alison Lawton

Alison Lawton

Board Member, Spyre Therapeutics

CrunchbaseLinkedIn

Alison Lawton's Career

Spyre Therapeutics
Spyre Therapeutics

Austin, TX, US

Board Member· Board
Kaleido Biosciences
Kaleido Biosciences

Lexington, MA, US

Board Member· Board
X4 Pharmaceuticals
X4 Pharmaceuticals

Boston, MA, US

Board Member· Board
AgBiome
AgBiome

Triangle (historical), NC, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Alison Lawton's Career

Spyre Therapeutics
Spyre Therapeutics
Public$266M692013Austin, TX, US
Board Member· Board

Leadership at Spyre Therapeutics

Cameron TurtleCameron TurtleCEO
David LoweDavid LoweFounder
Laurie StelzerLaurie StelzerBoard Member
Russell J. CoxRussell J. CoxBoard Member
Ivana Magovcevic-LiebischIvana Magovcevic-LiebischBoard Member

Similar to Spyre Therapeutics

Precision IBDPrecision IBDEncinitas, CA, USTherapeuticsest. 2016Precision IBDEncinitas, CA, US · est. 2016

Precision IBD: A biotech firm specializing in developing precise therapeutics for bowel diseases.

Series A · $13.8M30
Spyryx BiosciencesSpyryx BiosciencesDurham, NC, USTherapeuticsest. 2013Spyryx BiosciencesDurham, NC, US · est. 2013

US-based Spyryx Biosciences pioneers next-gen therapeutics for obstructive lung diseases since 2013.

Series A · $18.2M30
Osprey Pharmaceuticals USAOsprey Pharmaceuticals USASan Francisco, CA, USTherapeuticsest. 1998Osprey Pharmaceuticals USASan Francisco, CA, US · est. 1998

Osprey Pharmaceuticals USA: Innovating protein therapeutics for inflammatory and immune diseases.

Series A · $29.7M30
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Kaleido Biosciences
Kaleido Biosciences
Public$230.9M762015Lexington, MA, US
Board Member· Board

Leadership at Kaleido Biosciences

Noubar AfeyanNoubar AfeyanCo-Founder
Theo Melas-KyriaziTheo Melas-KyriaziBoard Member
Geoffrey von MaltzahnGeoffrey von MaltzahnCo-Founder
Anthony QuinnAnthony QuinnBoard Member
Mike BonneyMike BonneyBoard Member
Jean MixerJean MixerBoard Member
X4 Pharmaceuticals
X4 Pharmaceuticals
Public$542.9M722014Boston, MA, US
Board Member· Board

Leadership at X4 Pharmaceuticals

Richard PetersRichard PetersCo-Founder
Paula RaganPaula RaganCEO
Keith FlahertyKeith FlahertyBoard Member
Renato SkerljRenato SkerljCo-Founder
Mike WyzgaMike WyzgaBoard Member
William AliskiWilliam AliskiBoard Member
AgBiome
AgBiome
Series D$252.5M1392012Triangle (historical), NC, US
Board Member· Board

Leadership at AgBiome

Paul Schulze-LefertPaul Schulze-LefertCo-Founder
John RyalsJohn RyalsCo-Founder
Kristina BurowKristina BurowBoard Member
Scott UknesScott UknesCo-Founder
Marijn DekkersMarijn DekkersBoard Member
Amir NashatAmir NashatBoard Member

Similar to AgBiome

Boost BiomesBoost BiomesSouth San Francisco, CA, USBiological Productsest. 2016Boost BiomesSouth San Francisco, CA, US · est. 2016

Boost Biomes, Inc.: Innovating unique biological products through proprietary microbiome technology in the US.

Series A · $4.2M
Ascribe BioscienceAscribe BioscienceIthaca, NY, USCrop Protectionest. 2017Ascribe BioscienceIthaca, NY, US · est. 2017

Ascribe Bioscience: Developing eco-friendly products to boost crop defenses against pathogens since 2017.

Seed · $7.2M8
AgrynexAgrynexIthaca, NY, USBiopesticides, Crop Protectionest. 2015AgrynexIthaca, NY, US · est. 2015

Agrynex: Providing biocidal enzymes for crop protection against soil-borne diseases.

Angel · $50k4
Pivot BioPivot BioBerkeley, CA, USAgricultural Productsest. 2010Pivot BioBerkeley, CA, US · est. 2010

Pivot Bio, Inc.: A US-based AgriTech firm innovating plant nutrition by harnessing atmospheric nitrogen.

Series D · $616.9M488

Alison Lawton's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Alison Lawton

David IsraeliDavid IsraeliBoard Member · VisionCare Ophthalmic TechnologiesDave MottDave MottBoard Member · BioHealth InnovationDan LynchDan LynchBoard Member · 2seventy bioAlan ColowickAlan ColowickBoard Member · PersonalisMike RossMike RossBoard Member · Deciphera Pharmaceuticals